Overall, however, the existing literature implies that the benefits of SGLT-2 inhibitors in patients with type 2 diabetes and NASH far outweigh the potential adverse effects. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.